Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that specializes in the development, production, and marketing of a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Founded in 1978 in Amman, Jordan, by Samih Darwazah, it has grown to become a significant player in the global pharmaceutical industry, with a particular focus on the Middle East and North Africa (MENA) region, the United States, and Europe.
History[edit]
The foundation of Hikma Pharmaceuticals was laid by Samih Darwazah in 1978 in Amman, Jordan, with the vision of providing high-quality, affordable medicines to the Middle East and North Africa region. Over the years, Hikma has expanded its operations globally through strategic acquisitions and by establishing a strong presence in key markets, including the United States and Europe. The company's growth strategy has been focused on expanding its product portfolio, enhancing its manufacturing capabilities, and entering new markets.
Operations[edit]
Hikma Pharmaceuticals operates through three main business segments: Branded, Generics, and Injectables. The Branded division focuses on developing and marketing a wide range of branded generic pharmaceutical products in the MENA region. The Generics division offers a broad portfolio of non-branded generic pharmaceutical products primarily in the United States. The Injectables division provides a variety of generic injectable products used in hospitals worldwide.
The company has state-of-the-art manufacturing facilities and research and development (R&D) centers across its key markets. This infrastructure supports Hikma's commitment to quality and compliance with international regulatory standards.
Products[edit]
Hikma Pharmaceuticals' product portfolio includes a wide range of pharmaceutical products across multiple therapeutic areas, including cardiovascular, diabetes, oncology, anti-infective, and respiratory diseases, among others. The company's focus on both branded and generic medicines allows it to cater to a diverse customer base and meet various healthcare needs.
Corporate Social Responsibility[edit]
Hikma Pharmaceuticals places a strong emphasis on corporate social responsibility (CSR). The company is committed to improving healthcare access and outcomes in underserved communities, promoting environmental sustainability, and upholding high ethical standards in its operations.
Financial Performance[edit]
As a publicly traded company, Hikma Pharmaceuticals has shown consistent financial growth. The company's financial performance is reflected in its annual revenue, profit margins, and market capitalization, making it one of the leading pharmaceutical companies in the regions it operates.
Challenges and Opportunities[edit]
The pharmaceutical industry is highly competitive and subject to significant regulatory scrutiny. Hikma Pharmaceuticals faces challenges such as regulatory compliance, market competition, and the need for continuous innovation. However, the company's strong market position, diversified product portfolio, and strategic focus on growth markets present significant opportunities for expansion and development.
Conclusion[edit]
Hikma Pharmaceuticals has established itself as a key player in the global pharmaceutical industry through its commitment to quality, innovation, and accessibility of healthcare. With its strategic focus on growth markets and expanding product portfolio, Hikma is well-positioned to continue its trajectory of growth and make a positive impact on global health outcomes.
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian